# Eric Delbridge
Eric Delbridge is a physician-investor who serves as General Partner, Public Equity at [Sofinnova Venture Partners](https://www.edgepedia.org/sofinnova-venture-partners) (also operating as Sofinnova Investments), where he leads the Sofinnova BioEquities strategy, the firm's public-market long/short fund dedicated to global therapeutics companies.[1](https://people.equilar.com/bio/person/eric-delbridge-sofinnova-investments-inc/34376008) • [5](https://yespress.io/eric-delbridge) His Sofinnova biography states that he is responsible for developing the BioEquities strategy and has more than ten years of hedge fund investing experience in public therapeutics.[1](https://people.equilar.com/bio/person/eric-delbridge-sofinnova-investments-inc/34376008) He joined the firm in 2016 from Balyasny Asset Management, a global multi-strategy hedge fund, where he managed market-neutral therapeutics and healthcare portfolios.[1](https://people.equilar.com/bio/person/eric-delbridge-sofinnova-investments-inc/34376008)
Delbridge is a physician, holding an M.D. from [Northwestern University](https://www.edgepedia.org/northwestern-university), and his mandate is public equities rather than venture-stage company building. He is listed alongside James I. Healy and Anand Mehra as members of Sofinnova Bioequities Gp LLC, a Delaware limited liability company registered in California on July 13, 2016, consistent with the BioEquities strategy's launch that year.[2](https://www.corporationwiki.com/p/2s8qyj/sofinnova-bioequities-gp-llc)
| Key facts | Detail |
|---|---|
| Firm and role | General Partner, Public Equity, Sofinnova Venture Partners / Sofinnova Investments; leads Sofinnova BioEquities[1](https://people.equilar.com/bio/person/eric-delbridge-sofinnova-investments-inc/34376008) |
| Joined Sofinnova | 2016, from Balyasny Asset Management[1](https://people.equilar.com/bio/person/eric-delbridge-sofinnova-investments-inc/34376008) |
| GP entity formation | Sofinnova Bioequities Gp LLC filed July 13, 2016, with Healy, Delbridge, and Mehra as members[2](https://www.corporationwiki.com/p/2s8qyj/sofinnova-bioequities-gp-llc) |
| BioEquities fund sizes | Enhanced Master Fund, LP: $1.2B AUM, 28 LPs (Mar 2026); Master Fund, Ltd.: $121.4M, 50 LPs (Mar 2026)[3](https://fundraisingfox.com/investors/sofinnova-ventures) |
| Fund officer roles | Director, Sofinnova Bioequities Enhanced Offshore Fund Ltd (SEC file 021-461677, ~$226.3M raised); Executive Officer, Sofinnova Synergy Master Fund LP (021-405750, ~$4.9M)[4](https://aum13f.com/person/eric-delbridge) |
| Education | M.D., Northwestern University; M.B.A., Wharton School (Palmer Scholar); B.A. in Classics cum laude, Yale University[1](https://people.equilar.com/bio/person/eric-delbridge-sofinnova-investments-inc/34376008) |
| Regulatory record | No enforcement actions, sanctions, or adverse disclosures found in the aggregated SEC record through 2026[4](https://aum13f.com/person/eric-delbridge) |
## Early life and education
Delbridge trained in both medicine and finance. His Sofinnova biography states that he received his M.D. from Northwestern University and his M.B.A. from the [Wharton School](https://www.edgepedia.org/wharton-school) of the University of Pennsylvania, where he was a Palmer Scholar, and that he graduated cum laude with a B.A. in Classics from Yale University.[1](https://people.equilar.com/bio/person/eric-delbridge-sofinnova-investments-inc/34376008)
He began his career in healthcare investment banking at Lazard and [Credit Suisse](https://www.edgepedia.org/credit-suisse), where his Sofinnova biography says he focused on biotech mergers and acquisitions.[1](https://people.equilar.com/bio/person/eric-delbridge-sofinnova-investments-inc/34376008) That M&A background preceded his move to the buy side: he became a Partner at Spring Point Capital, formerly Botti Brown Asset Management, a long/short equity hedge fund where he focused on healthcare investments, before managing market-neutral therapeutics and healthcare portfolios at Balyasny Asset Management.[1](https://people.equilar.com/bio/person/eric-delbridge-sofinnova-investments-inc/34376008)
## Role at Sofinnova: the BioEquities mandate
The BioEquities strategy Delbridge leads is a public-equity long/short strategy focused on global therapeutics companies: it buys and shorts shares of publicly traded therapeutics companies globally rather than taking private positions in start-ups.[1](https://people.equilar.com/bio/person/eric-delbridge-sofinnova-investments-inc/34376008) • [5](https://yespress.io/eric-delbridge)
The scale of the strategy is documented in SEC-derived filings data. As of March 2026, Sofinnova BioEquities Enhanced Master Fund, LP reported approximately $1.2 billion in assets under management with 28 limited partners, and Sofinnova BioEquities Master Fund, Ltd. reported $121.4 million with 50 limited partners.[3](https://fundraisingfox.com/investors/sofinnova-ventures) A second-hand figure of roughly $1.5 billion for the strategy overall appears in a single directory profile and cannot be independently verified; the filing-derived fund totals above are the firmer numbers.
The firm's filings also name Delbridge as a Director of Sofinnova Bioequities Enhanced Offshore Fund Ltd (SEC file number 021-461677), which raised approximately $226.3 million, and as an Executive Officer of Sofinnova Synergy Master Fund LP (SEC file number 021-405750), which raised approximately $4.9 million.[4](https://aum13f.com/person/eric-delbridge) These are officer designations within the fund entities he manages; no independent corporate board seats outside Sofinnova's own fund structures appear in the available record.
## By the numbers
The BioEquities funds are a material part of Sofinnova's business. Firm-wide, Sofinnova Investments is reported to hold approximately US$4.4 billion in assets under management and committed capital as of 2025, though the same directory elsewhere states $5.4 billion, a discrepancy that remains unresolved.[3](https://fundraisingfox.com/investors/sofinnova-ventures)
For context on the venture franchise whose returns BioEquities supplements, directory-sourced fund data show net IRRs of 21.9% for Sofinnova Venture Partners VIII (2011 vintage, 1.66x TVPI), 14.7% for Fund VII (2007 vintage), and 7.2% for Fund IX (2014 vintage), with Fund VI (1999) at -19.8%.[3](https://fundraisingfox.com/investors/sofinnova-ventures) The newer funds are early in their lives: Fund XII (vintage 2024) reported $20.5 million in AUM with 75 LPs, and Fund XI (vintage 2021) reported $308.7 million with 52 LPs.[3](https://fundraisingfox.com/investors/sofinnova-ventures)
## Recent developments
Sofinnova's public-market activity between 2024 and 2026, the period in which BioEquities filings are visible, centers on three stake disclosures: an SC 13G in ArriVent BioPharma filed in November 2024, an SC 13D in [BioAge Labs](https://www.edgepedia.org/bioage-labs) filed in September 2024, and an SC 13D in [Rapport Therapeutics](https://www.edgepedia.org/rapport-therapeutics) filed in June 2024.[3](https://fundraisingfox.com/investors/sofinnova-ventures) These are firm-level filings; the sources do not attribute individual positions to Delbridge personally, which is typical when an officer manages a fund's book.
## References
1. Eric Delbridge MD - Executive Bio, Work History, and Contacts, Equilar ExecAtlas, https://people.equilar.com/bio/person/eric-delbridge-sofinnova-investments-inc/34376008
2. Sofinnova Bioequities Gp LLC in Menlo Park CA, Corporation Wiki, https://www.corporationwiki.com/p/2s8qyj/sofinnova-bioequities-gp-llc
3. Sofinnova Ventures - Investment Thesis, Check Size & Team, Fundraising Fox, https://fundraisingfox.com/investors/sofinnova-ventures
4. Eric Delbridge, AUM 13F, https://aum13f.com/person/eric-delbridge
5. Eric Delbridge - General Partner, Sofinnova Investments, YesPress, https://yespress.io/eric-delbridge
---
*Topic: Encyclopedia › Society and history › Economics and business › Founders, operators, and investors › Venture and growth investors › Life-science venture and company creation › Biotech venture capital partners › Titles A to J*
*Initially written Sep 17, 2026 · Edited: Oct 11, 2026; Oct 15, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license